These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8872324)

  • 1. Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine.
    Green JA; Slater AJ; Campbell IR; Kelly V
    Breast Cancer Res Treat; 1996; 39(2):155-63. PubMed ID: 8872324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.
    Powles TJ; Jones AL; Judson IR; Hardy JR; Ashley SE
    Br J Cancer; 1991 Aug; 64(2):406-10. PubMed ID: 1892775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone combined with vincristine, cyclophosphamide and fluorouracil for advanced breast cancer. A study of short-term response rate.
    Misset JL; Metz R; Gil-Delgado M; Keiling R; Cappelaere P; Armand JP; Prévot G; Grimbert J; Mathé G; Hibberd M
    Anticancer Res; 1987; 7(4B):737-40. PubMed ID: 3674760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
    Fumoleau P; Chauvin F; Namer M; Bugat R; Tubiana-Hulin M; Guastalla JP; Delozier T; Kerbrat P; Devaux Y; Bonneterre J; Filleul A; Clavel M
    J Clin Oncol; 2001 Feb; 19(3):612-20. PubMed ID: 11157010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
    Heidemann E; Steinke B; Hartlapp J; Schumacher K; Possinger K; Kunz S; Neeser E; von Ingersleben G; Hossfeld D; Waldmann R
    Onkologie; 1990 Feb; 13(1):24-7. PubMed ID: 2186320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
    Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer.
    Ransom DT; Neuberg D; Loprinzi CL; Tormey DC; Blum RH; Harris JE; Asbury RF; Falkson G
    Am J Clin Oncol; 1991 Feb; 14(1):45-8. PubMed ID: 1898999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine.
    Bezwoda WR; Dansey R; Seymour L
    Oncology; 1989; 46(4):208-11. PubMed ID: 2740063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial.
    Gundersen S; Kvinnsland S; Klepp O; Kvaløy S; Lund E; Høst H
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1431-4. PubMed ID: 3595668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast. A phase III study of the Piedmont Oncology Association (POA).
    Zekan PJ; Muss HB; Capizzi RL; Cooper MR; Harding RW; Hopkins JO; Jackson DV; Ramseur WL; Richards F; Spurr CL
    Cancer; 1984 Dec; 54(11):2338-43. PubMed ID: 6388802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
    Heidemann E; Stoeger H; Souchon R; Hirschmann WD; Bodenstein H; Oberhoff C; Fischer JT; Schulze M; Clemens M; Andreesen R; Mahlke M; König M; Scharl A; Fehnle K; Kaufmann M
    Ann Oncol; 2002 Nov; 13(11):1717-29. PubMed ID: 12419743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
    J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.
    Stewart DJ; Evans WK; Shepherd FA; Wilson KS; Pritchard KI; Trudeau ME; Wilson JJ; Martz K
    J Clin Oncol; 1997 May; 15(5):1897-905. PubMed ID: 9164200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of cyclophosphamide-mitoxantrone-5-fluorouracil v cyclophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer: preliminary observations.
    Stewart DJ; Maroun JA; Hirte W; Perrault D; Stolbach L; Cripps C; Lefebvre B
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):23-7. PubMed ID: 6385261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer.
    Budd GT; Atiba J; Silver RT; Palmer G; Armstrong S; Otto K; Presant C
    J Cancer Res Clin Oncol; 1999; 125(8-9):500-4. PubMed ID: 10480343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.